Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

The penalty, equivalent to MXN 6,51,420, was levied due to non-compliance with Mexico’s guidelines for import filings related ...

Donald Trump 's return to the US presidency could have a major impact on India's pharmaceutical industry. The US is the ...

This year's award marks 30 years since clinicians first used ECP to successfully treat chronic graft versus host disease (cGvHD).1 In recognition of this important milestone, this year's $75,000 grant ...

Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals, such as ...

“Compounded products claiming to contain semaglutide have not undergone verification nor evaluation by Sahpra to assess ...

As of now, no API (Active Pharmaceutical Ingredient) for medical cannabis has been registered." She explained that medical ...

Generic drugmaker Natco Pharma consolidated net profit surged 83% to ₹676.5 crore for the quarter ended September, from ₹369 ...

Pharma player Granules India Limited on Friday said it has received an Establishment Inspection Report (EIR) from the US Food ...

The unlisted ingredients can cause "life threatening" drops in blood pressure when used in combination with other prescription drugs.

Granules India announced that it has received an establishment inspection report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Unit V facility located at Jawaharlal Nehru Pharma ...